MILFORD, Mass.--(BUSINESS WIRE)--March 5, 2004--Waters Corporation (NYSE:WAT) announced today it has completed the acquisition of NuGenesis Technologies of Westborough, MA. On January 28, Waters announced it had entered into a definitive merger agreement to acquire the outstanding capital stock of privately-held NuGenesis for approximately $43 million.
Waters will be exhibiting its new suite of informatics products, including the Waters(R) NuGenesis SDMS products, in booth 1454 at Pittcon 2004, March 8 - 11 in Chicago.
Commenting on the acquisition, Art Caputo, President - Waters Division, said, "Waters has had a well-established position in chromatography and mass spectrometry data management. With the 2003 acquisition of Creon Lab Control and the more recent purchase of NuGenesis Technologies, Waters now has a comprehensive range of products for scientific data management. We are now much more than an instrument company."
At a press conference scheduled for Monday, March 8, from 8:30 - 9:30 a.m. at McCormick Place, Chicago, Illinois, in Room S105A, Waters will outline its plans to offer science-based companies a broader array of informatics tools aimed at increasing laboratory productivity by managing scientific data more efficiently.
About Waters Corporation
Waters Corporation holds worldwide leading positions in three complementary analytical technologies - high performance liquid chromatography (HPLC), mass spectrometry (MS) and thermal analysis (TA). These markets account for $4.4 billion of the overall $20 billion analytical instrumentation market. For further information about Waters Division products and services, please visit www.waters.com.
Waters, NuGenesis, and NuGenesis SDMS are trademarks of Waters Corporation.
Certain statements contained herein are forward looking. Many factors could cause actual results to differ from these statements, including delays in product introductions, loss of market share through competition, introduction of competing products by other companies, pressures on prices from competitors and/or customers, regulatory obstacles to new product introductions, lack of acceptance of new products, changes in the healthcare market and the pharmaceutical industry, changes in distribution of the Company's products, and foreign exchange fluctuations. Such factors are discussed in detail in the Company's filings with the Securities and Exchange Commission.